The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| FDMT | +38.12% | N/A | N/A | -75% |
| S&P | +16.9% | +95.99% | +14.39% | +85% |
4D Molecular Therapeutics, Inc. operates as a clinical stage biotherapeutics company, which engages in the design, development, and commercialization of transformative gene therapeutic products for serious unmet medical conditions. It offers products for ophthalmology, cardiology, and pulmonology. The company was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.02M | 200.0% |
| Gross Profit | -$1.87M | -15.7% |
| Gross Margin | -12486.67% | 19893.3% |
| Market Cap | $171.86M | -84.2% |
| Market Cap / Employee | $0.76M | 0.0% |
| Employees | 227 | 0.0% |
| Net Income | -$54.66M | -56.4% |
| EBITDA | -$57.57M | -41.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $69.72M | -63.1% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $17.36M | 65.9% |
| Short Term Debt | $5.72M | 79.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -35.87% | 0.0% |
| Return On Invested Capital | -29.86% | 26.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$43.44M | -42.0% |
| Operating Free Cash Flow | -$43.38M | -43.4% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.95 | 0.52 | 0.29 | 0.37 | -86.51% |
| Price to Sales | 6893.84 | 7828.40 | 6287.56 | - | |
| Price to Tangible Book Value | 0.95 | 0.52 | 0.29 | 0.37 | -86.51% |
| Enterprise Value to EBITDA | -2.50 | 2.67 | 2.27 | 1.09 | -107.03% |
| Return on Equity | -33.0% | -38.9% | - | ||
| Total Debt | $24.83M | $24.61M | $23.85M | $23.08M | 68.99% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
